Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Merck KGaA
Acquired Company
Silence Therapeutics
Darmstadt
LondonBiotechnologyHealth CareBiotechnologyHealth CareTherapeuticsDescription
Merck KGaA has entered into a definitive agreement to acquire Silence Therapeutics plc for $20 per ADS in cash. This acquisition aims to strengthen Merck's rare disease pipeline with Silence's innovative siRNA asset. Silence Therapeutics focuses on developing therapies in areas of high unmet need, enhancing Merck's commitment to transformative healthcare solutions.
Fundz sees it the moment Merck KGaA makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Silence Therapeutics?
Silence Therapeutics was acquired by Merck KGaA, based in Darmstadt. The deal was reported on October 19, 2026. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. Merck KGaA is privately held and operates in Biotechnology.
When did Merck KGaA acquire Silence Therapeutics?
Merck KGaA's acquisition of Silence Therapeutics was reported on October 19, 2026. Merck KGaA has entered into a definitive agreement to acquire Silence Therapeutics plc for $20 per ADS in cash. This acquisition aims to strengthen Merck's rare disease pipeline with Silence's innovative siRNA asset. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Silence Therapeutics do?
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. It is publicly traded (SLN), operating in Biotechnology, and is based in London.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.